ES2097790T3 - Uso de l-deprenilo para retardar el deterioro debido al envejecimiento. - Google Patents

Uso de l-deprenilo para retardar el deterioro debido al envejecimiento.

Info

Publication number
ES2097790T3
ES2097790T3 ES91302820T ES91302820T ES2097790T3 ES 2097790 T3 ES2097790 T3 ES 2097790T3 ES 91302820 T ES91302820 T ES 91302820T ES 91302820 T ES91302820 T ES 91302820T ES 2097790 T3 ES2097790 T3 ES 2097790T3
Authority
ES
Spain
Prior art keywords
deprenyl
aging
deterioration due
delay deterioration
frequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91302820T
Other languages
English (en)
Inventor
Norton W Milgram
David R Stevens
Gwendolyn O Ivy
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Deprenyl Animal Health Inc
Original Assignee
Deprenyl Animal Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27076843&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2097790(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US07/576,011 external-priority patent/US5151449A/en
Application filed by Deprenyl Animal Health Inc filed Critical Deprenyl Animal Health Inc
Application granted granted Critical
Publication of ES2097790T3 publication Critical patent/ES2097790T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Thin Film Transistor (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Insulating Materials (AREA)
  • Pulse Circuits (AREA)
  • Electrotherapy Devices (AREA)

Abstract

L-DEPRENIL Y FORMAS ANALOGAS FARMACEUTICAMENTE ACEPTABLES DEL MISMO SE UTILIZAN EN NIVELES DE DOSIS ESPECIFICAS Y FRECUENCIA DE DOSIS PARA RETARDAR EL DETERIORO DE LA FUNCION RENAL DEPENDIENTE DE LA EDAD NORMAL, PARA PROPORCIONAR UN NIVEL DE COMPORTAMIENTO EXPLORATORIO AUMENTADO DE LA ACTIVIDAD A CUALQUIER EDAD PROPORCIONADA A FIN DE RETARDAR EL DETERIORO CAUSADO POR LA EDAD DE LAS CAPACIDADES COGNOCITIVAS, ESPECIALMENTE DE LA CAPACIDAD DEL CONOCIMIENTO ESPACIAL ASI COMO PARA MANTENER UNA FUNCION SUPRARRENAL, FUNCION TIROIDAL, FUNCION DEL SISTEMA DE INMUNIDAD NORMAL Y COMPOSICION DEL CUERPO EN MAMIFEROS ADULTOS. EL TRATAMIENTO PODRA SER ESPECIFICAMENTE UTIL PARA MASCOTAS TALES COMO PERROS Y GATOS.
ES91302820T 1990-08-31 1991-03-28 Uso de l-deprenilo para retardar el deterioro debido al envejecimiento. Expired - Lifetime ES2097790T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/576,011 US5151449A (en) 1990-08-31 1990-08-31 Use of L-deprenyl for retention of specific physiological functions
US64345291A 1991-01-18 1991-01-18

Publications (1)

Publication Number Publication Date
ES2097790T3 true ES2097790T3 (es) 1997-04-16

Family

ID=27076843

Family Applications (2)

Application Number Title Priority Date Filing Date
ES96103701T Expired - Lifetime ES2135123T3 (es) 1990-08-31 1991-03-28 Uso de l-deprenilo para retardar el deterioro dependiente de la edad de la funcion del sistema inmunitario en mamiferos.
ES91302820T Expired - Lifetime ES2097790T3 (es) 1990-08-31 1991-03-28 Uso de l-deprenilo para retardar el deterioro debido al envejecimiento.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES96103701T Expired - Lifetime ES2135123T3 (es) 1990-08-31 1991-03-28 Uso de l-deprenilo para retardar el deterioro dependiente de la edad de la funcion del sistema inmunitario en mamiferos.

Country Status (16)

Country Link
US (2) US5276057A (es)
EP (2) EP0732101B1 (es)
JP (3) JP2819072B2 (es)
AT (2) ATE149350T1 (es)
AU (1) AU633714B2 (es)
BR (1) BR9103506A (es)
CA (1) CA2039194C (es)
DE (2) DE69124875T2 (es)
DK (2) DK0732101T3 (es)
ES (2) ES2135123T3 (es)
GR (2) GR3022971T3 (es)
HK (1) HK1011611A1 (es)
ID (1) ID19492A (es)
MX (1) MX9100067A (es)
MY (2) MY124210A (es)
NZ (1) NZ238277A (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5565495A (en) * 1990-08-31 1996-10-15 Deprenyl Animal Health, Inc. Method for survival curve shifting in dogs
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same
US5561163A (en) * 1990-08-31 1996-10-01 Deprenyl Animal Health, Inc. Treating hearing loss with deprenyl
US5767164A (en) * 1991-04-04 1998-06-16 Innovations Foundation Use of deprenyl to rescue damaged nerve cells
US5844003A (en) * 1991-04-04 1998-12-01 Innovations Foundation Use of deprenyl compounds to maintain, prevent loss, or recover nerve cell function
US5444095A (en) * 1991-04-04 1995-08-22 University Of Toronto, Innovations Foundation Use of deprenyl to rescue damaged nerve cells
EP1413299A3 (en) * 1991-04-04 2004-05-06 The University Of Toronto Innovations Foundation Use of deprenyl analogues to maintain, prevent loss, or recover nerve cell function
US5242950A (en) * 1992-04-23 1993-09-07 Somerset Pharmaceuticals, Inc. Treatment of macular degeneration
US5817336A (en) * 1993-04-02 1998-10-06 Orion-Yhtyma Oy Composition containing selegiline
FR2704756B1 (fr) * 1993-05-04 1995-07-28 Sanofi Elf Utilisation de la sélégiline en médecine vétérinaire.
EP0623344B1 (fr) * 1993-05-04 2000-07-26 Ceva Sante Animale Utilisation de la Sélégiline en médecine vetérinaire
WO1996022068A2 (en) 1995-01-13 1996-07-25 Somerset Pharmaceuticals, Inc. Methods and pharmaceutical compositions employing desmethylselegiline
US6033682A (en) 1995-01-13 2000-03-07 Somerset Pharmaceuticals, Inc. S(+) desmethylselegiline and its use in therapeutic methods and pharmaceutical compositions
CA2212412A1 (en) * 1995-02-10 1996-08-15 The University Of Toronto Innovations Foundation Deprenyl compounds for treatment of glaucoma
US6316022B1 (en) 1995-06-07 2001-11-13 Noven Pharmaceuticals, Inc. Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures
JPH11506744A (ja) 1995-06-07 1999-06-15 ノウブン ファーマシューティカルズ インク． 室温で液体である低分子量薬を含む経皮組成物
AU707646B2 (en) * 1995-11-06 1999-07-15 Somerset Pharmaceuticals, Inc. Sublingual and buccal administration of selegiline
WO1999047133A1 (en) * 1998-03-16 1999-09-23 Somerset Pharmaceuticals, Inc. Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage
US20030212144A1 (en) * 2001-07-18 2003-11-13 Mohankumar Sheba J.J. Method for inducing an estrous cycle and pregnancy in a female mammal
AU2003282337B2 (en) * 2002-11-07 2009-07-16 Technion Research And Development Foundation Ltd. Neuroprotective iron chelators and pharmaceutical compositions comprising them
US20050009862A1 (en) * 2003-04-25 2005-01-13 Sabounjian Luann Method for promoting uninterrupted sleep by administration of trospium chloride
US8097608B2 (en) * 2003-11-25 2012-01-17 Technion Research And Development Foundation Ltd. Methods for treatment of cardiovascular disorders and diseases
CA2547053C (en) * 2003-11-25 2014-05-27 Technion Research & Development Foundation Ltd. Compositions and methods for treatment of cardiovascular disorders and diseases
JP2005232148A (ja) * 2004-02-03 2005-09-02 Technion Research & Development Foundation Ltd 神経保護剤としてプロパルギルアミンの使用
FR2884421B1 (fr) 2005-04-15 2007-08-10 Virbac Sa Nouveaux moyens de regulation des troubles du comportement chez les animaux de compagnie
US8263655B2 (en) 2005-10-06 2012-09-11 Technion Research And Development Foundation Ltd Methods for treatment of renal failure
AU2010336985B2 (en) 2009-12-29 2013-09-19 Hill's Pet Nutrition, Inc. Compositions including pyruvate for companion animals and methods of use thereof
HUE044221T2 (hu) 2010-02-03 2019-10-28 Pharma Two B Ltd Nyújtott hatóanyagleadású razagilin készítmények és alkalmazásaik
CN103860503A (zh) * 2012-12-10 2014-06-18 天津市汉康医药生物技术有限公司 一种治疗帕金森病的缓释药物组合物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA871155A (en) * 1971-05-18 Chinoin Gyogyszer-Es Vegyeszeti Termekek Gyara Rt Optically active phenyl isopropylamine derivatives having pharmaceutical properties and their preparation
HU187775B (en) * 1982-07-14 1986-02-28 Chinoin Gyogyszer Es Vegyeszeti Termekek Gyara Rt,Hu New process for producing propargile-amines of pharmaceutical activity
US4916151A (en) * 1985-12-05 1990-04-10 Merrell Dow Pharmaceuticals Inc. Method of treating parkinson's syndrome
US4871550A (en) * 1986-09-05 1989-10-03 Millman Phillip L Nutrient composition for athletes and method of making and using the same
US4880883A (en) * 1987-06-03 1989-11-14 Wisconsin Alumni Research Foundation Biocompatible polyurethanes modified with lower alkyl sulfonate and lower alkyl carboxylate
US4861800A (en) * 1987-08-18 1989-08-29 Buyske Donald A Method for administering the drug deprenyl so as to minimize the danger of side effects
HU208484B (en) * 1988-08-17 1993-11-29 Chinoin Gyogyszer Es Vegyeszet Process for producing pharmaceutical composition containing acid additional salt of selegilin as active component for treating schisofrenia
US5192808A (en) * 1990-08-31 1993-03-09 Deprenyl Animal Health, Inc. Therapeutic effect of L-deprenyl in the management of pituitary-dependent hyperadrenocorticism (cushing's disease)
CA2039194C (en) * 1990-08-31 1997-01-28 Norton W. Milgram Uses of l-deprenyl and compositions for same

Also Published As

Publication number Publication date
HK1011611A1 (en) 1999-07-16
JP2884500B2 (ja) 1999-04-19
MY110217A (en) 1998-03-31
JPH09328422A (ja) 1997-12-22
JPH09328423A (ja) 1997-12-22
ATE149350T1 (de) 1997-03-15
MX9100067A (es) 1992-04-01
AU7395791A (en) 1992-03-05
EP0732101B1 (en) 1999-06-23
EP0473252A2 (en) 1992-03-04
EP0732101A1 (en) 1996-09-18
NZ238277A (en) 1993-10-26
GR3031263T3 (en) 1999-12-31
MY124210A (en) 2006-06-30
DE69124875D1 (de) 1997-04-10
ES2135123T3 (es) 1999-10-16
JP2819072B2 (ja) 1998-10-30
DK0473252T3 (da) 1997-09-15
DK0732101T3 (da) 1999-11-22
AU633714B2 (en) 1993-02-04
DE69124875T2 (de) 1997-06-26
EP0473252A3 (en) 1992-08-05
EP0473252B1 (en) 1997-03-05
DE69131386D1 (de) 1999-07-29
US5387615A (en) 1995-02-07
BR9103506A (pt) 1992-05-12
CA2039194A1 (en) 1992-03-01
ATE181501T1 (de) 1999-07-15
JPH04230624A (ja) 1992-08-19
CA2039194C (en) 1997-01-28
ID19492A (id) 1998-07-16
DE69131386T2 (de) 1999-11-25
JP2884501B2 (ja) 1999-04-19
US5276057A (en) 1994-01-04
GR3022971T3 (en) 1997-06-30

Similar Documents

Publication Publication Date Title
ES2097790T3 (es) Uso de l-deprenilo para retardar el deterioro debido al envejecimiento.
MX9101046A (es) Anticuerpos novedosos para el tratamiento y prevencion de infeccion de animales y el hombre
DE68914856D1 (de) Synergetische Antioxydationsmischung.
MX164233B (es) Composicion de caucho modificada con nylon
SE8700203D0 (sv) Pyroglutamide derivatives
DE3851456D1 (de) Synergetische immunostimulierende Zusammensetzung und ihre Verwendung.
IT1229223B (it) Composizioni veterinarie sinergisticamente attive e procedimento per la loro preparazione.
MX164619B (es) Composicion para el tratamiento de lesiones cutaneas
IT1211635B (it) Metodo per aumentare il regime di crescita di animali e composizione in esso impiegata
ITTO930024A1 (it) Composizione per accelerare la rimarginazione di ferite
ES2094240T3 (es) Utilizacion de diol diesteres en los alimentos para perros y gatos.
ES2019583B3 (es) Composicion para el tratamiento de infecciones.
FR2638212B1 (fr) Ecrou autobloquant perfectionne
BR9106596A (pt) Processo para o tratamento ou profilaxia de uma infeccao associada com retrovirus,uso,composicao farmaceutica para o tratamento ou profilaxia de uma infeccao associada com retrovirus,e,composto
KR900002681A (ko) 상승효과를 가지는 약학적 조성물
MX17601A (es) Composicion para el tratamiento de leishmaniasis yprocedimiento para su preparacion .
ES1007395Y (es) Dispositivo para la preparacion de pescados de la especie carangidae.
ES1001196Y (es) Dispositivo perfeccionado para la eliminacion de insectos
IT1171125B (it) Composizione per uso orale particolarmente destinata al trattamento terapeutico di animali
MX9203089A (es) Composicion para el tratamiento de esquisofrenia.
IT1227682B (it) Composizioni antidiarroiche per uso umano e veterinario
ES280608Y (es) Dispositivo perfeccionado para el cultivo mecanico de la vid
ES285318Y (es) Tapete perfeccionado para el juego del mus
ES266110Y (es) Disposicion perfeccionada en pernios para anclaje de suje- cion.
ES1005715Y (es) Camilla perfeccionada para el transporte de cadaveres

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 473252

Country of ref document: ES